Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

The National Health Service (NHS) England is launching a nationwide program to make optical coherence tomography (OCT) scans more accessible, aiming to improve outcomes for patients with diabetic retinopathy. This initiative will bring advanced imaging technology closer to home for…

A recent Chinese study has shed light on the prevalence and influencing factors of ocular pain in individuals suffering from dry eye disease (DED) residing at high altitudes on the Tibetan Plateau. Co-authored by Peng-Cheng Zhang, MD, PhD, and Wen-Shan…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept. This development marks a significant milestone in expanding affordable…
The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: report 19, a comparative study of the cost and carbon footprint of local anaesthesia techniques for cataract surgery | Eye Nature Source: Author: | Date: 2024-11-23 08:00:00 Source: Author:…

The California Institute for Regenerative Medicine (CIRM) has awarded a $6 million, two-year grant to researchers at the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute. This funding will advance preclinical studies…

Adverum Biotechnologies has released promising 52-week topline results from its Phase 2 LUNA trial and new 4-year data from the Phase 1/2 OPTIC study for its gene therapy candidate Ixo-vec (AAV.7m8-aflibercept), targeting wet age-related macular degeneration (AMD). Transformative Potential of…

Emmecell has announced positive results from its U.S. multicenter Phase 1 trial evaluating EO2002, an innovative non-surgical cell therapy for corneal edema. The randomized, double-masked trial demonstrated significant improvements in best corrected visual acuity (BCVA) and reductions in central corneal…
Pilot and feasibility studies in ophthalmology: fundamental keys to success – Eye Nature Source: Author: | Date: 2024-11-21 08:00:00 Source: Author: | Date: 2024-11-21 08:00:00
Ophthalmology demand-capacity management in South East London through a single point of access (SPoA): a new model using NHS eRS | Eye Nature Source: Author: | Date: 2024-11-21 08:00:00 Source: Author: | Date: 2024-11-21 08:00:00

Melt Pharmaceuticals has reported promising topline results from the pivotal Phase 3 trial of MELT-300, a novel, non-intravenous, non-opioid sedation tablet developed for use during cataract surgeries. The study, conducted under an FDA-approved Special Protocol Assessment (SPA) agreement, demonstrated that…